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The ultimate role of e-cigarettes in tobacco 
control, if any, remains to be determined. What can 
be said with confidence is that the market share 
for e-cigarettes will continue to grow over the next 
few years; that the legal and regulatory battles over 
e-cigarettes’ marketing will continue worldwide, 
while companies manufacturing and marketing 
e-cigarettes (including Big Tobacco) will continue 
to do so to the fullest extent permitted within local 
legal and regulatory climates; and that the desperately 
needed rigorous clinical trials examining e-cigarettes’ 
efficacy as cessation tools will be forthcoming. In 
the meantime, the study by Kalkhoran and Glantz 
suggests that e-cigarettes will not end the global 
pandemic of tobacco use.
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BMPR2 revisited: are bigger data better?
Since 2000, mutations in the gene that codes for the 
bone morphogenetic protein type II receptor (BMPR2) 
have been recognised as the major genetic cause of 
heritable pulmonary arterial hypertension (PAH) with a 
prevalence of about 80% in familial PAH and accounting 
for a substantial proportion of cases of sporadic PAH.1–3 
In The Lancet Respiratory Medicine, Jonathan Evans 
and colleagues4 report ﬁ ndings from an individual 
participant data meta-analysis from the BMPR2 
Studies Collaboration comprised of 1550 patients with 
idiopathic, heritable, and anorexigen-associated PAH 
from eight individual PAH cohorts from six countries. 
BMPR2 mutations were found in nearly 30% of patients 
and were associated with younger age at diagnosis, 
more severe haemodynamic derangement, and lower 
likelihood of vasoreactivity. In age-adjusted and sex-
adjusted models including 1164 patients, a BMPR2 
mutation was associated with an increased risk of death 
or lung transplantation (HR 1·42, 1·15–1·75) which 
might have been due to worse baseline cardiac function 
in BMPR2 mutation carriers.
This work represents a labour-intensive, multinational 
eﬀ ort to harmonise previously collected, patient-level 
data to more powerfully assess the eﬀ ect of BMPR2 
mutations. Data sharing at the individual patient 
level fosters collaboration across institutions and 
geographical regions and can enhance our knowledge 
beyond the results of any single study or cohort (as 
in this study).5 Sharing data from both observational 
studies and clinical trials will be crucial to achieve the full 
promise of omics technology, comparative eﬀ ectiveness 
research, and big data analytics to improve our 
understanding and treatment of pulmonary vascular 
disease. However, data sharing is not without barriers, 
including patient privacy rules (which might diﬀ er 
across countries), intellectual autonomy, and often 
substantial cost.
As opposed to a traditional meta-analysis (which 
uses aggregate data), an individual participant 
data meta-analysis analyses individual patient data 
from many studies. This study methodology aﬀ ords 
several advantages, including the use of consistent 
inclusion criteria across studies, follow-up information 
potentially beyond that available in the initial studies, 
accounting for missing data, detailed assessments 
of statistical assumptions, sensitivity and subgroup 
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analyses, better adjustment for confounders and 
examination of eﬀ ect modiﬁ cation, and enhanced 
statistical power, all of which were leveraged in this 
study.6
The authors were able to confirm a significant 
relation between BMPR2 mutations and worse 
transplant-free survival, an association that was 
significantly stronger in younger patients and 
unrelated to mutation subtype. The authors assessed 
haemodynamic parameters, including pulmonary 
vascular resistance, cardiac index, and vasoreactivity, 
as potentially mediating factors between BMPR2 
mutation status and outcome. Lower cardiac index at 
baseline accounted for most of the increase in risk for 
mutation carriers for both death or transplantation 
and all-cause mortality (65% and 79%, respectively). 
This finding is important as it confirms previous data 
showing the effect of cardiac index, a somewhat 
crude metric of right ventricular function, on survival 
in PAH in general, and in familial PAH specifically.7,8 It 
also implicates mutations in BMPR2 as contributors 
to right ventricular dysfunction, perhaps via 
perturbations in right ventricular metabolism and 
lipotoxicity, as previously described.9  Although the 
study is well executed, some questions remain. First, 
investigators used a one-stage stratified model for 
the primary analysis and a two-stage random effects 
model in a sensitivity analysis. The conclusions were 
similar, which is reassuring, but the I2 estimates 
from the latter indicate moderate heterogeneity, 
potentially reflecting differences in study designs or 
populations. Second, although significant, BMPR2 
mutations increased the risk of adverse outcomes by 
about 30–40% (though more so in younger patients). 
Thus, for the individual patient, the presence of a 
mutation might not have sufficient discriminatory 
power to tailor treatment or predict outcome. Genetic 
testing is recommended for patients with sporadic, 
familial, and anorexigen-associated PAH10 but 
experienced counselling is necessary for the patient 
and relatives considering the clinical and familial 
implications (and possible misinterpretations) of 
the presence of a mutation.3 A gene-based precision 
medicine treatment approach in this population 
should be studied.  
The work by Evans and colleagues4 revisits the 
role of BMPR2 mutations in a bigger and better way 
and shows how collaborative observational patient-
oriented studies can enlighten mechanisms of human 
PAH. Future studies are needed to understand the best 
approaches to genetic screening and counselling, the 
role of screening and preventative therapy in mutation 
carriers without clinical PAH and intensive therapy 
in mutation carriers with PAH, and haemodynamic 
response to therapy in mutation carriers compared 
with non-carriers. Furthermore, the use of common 
data elements and standardised mapping of variables 
to an ontology would facilitate the development 
of a master data structure and common protocol 
for pulmonary hypertension, facilitating data 
harmonisation and sharing of future observational 
studies and clinical trials. Appropriate consent for 
data sharing with appropriate protections should 
be obtained as standard, as should subject or global 
unique identiﬁ ers to denote the same patients (or 
distinguish diﬀ erent ones) in multiple centres or 
registries. If we “begin with the end in mind”11 and 
plan a priori for data sharing and harmonisation, we 
can best fulﬁ ll our ethical obligations to patients by 
making the most use of their substantial investments 
in research.
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 Of mice and men—the curious tale of β blockers in asthma 
Stimulation of airway β2-adrenoceptors (β2ADR) 
by shortacting or longacting β agonists (LABA) via 
the classic (canonical) G protein cyclic adenosine 
monophosphate (Gs-cAMP) signalling pathway results 
in bronchodilation and relief of asthma symptoms. 
However, β2-agonists can also activate non-canonical 
(Gs-cAMP independent) β-arrestin mediated 
proinﬂ ammatory signalling pathways via extracellular 
signal regulated kinases (ERK1/2).1 In knockout mice, 
β-arrestin-2 regulates the development of allergic 
asthma.2 Chronic exposure to LABA causes adaptive 
downregulation and uncoupling of β2ADR with 
associated subsensitivity of response and in some cases 
worse asthma control.3 In the antigen-driven mouse 
model, depletion of adrenaline, the natural ligand for 
the β2ADR, prevented the development of asthma.4 
Replacement of β2ADR signalling by administration of 
the LABA formoterol restored the asthma phenotype, 
showing that agonist induced activation of β2ADR 
results in the development of asthma.4 This ﬁ nding 
suggests paradoxically that use of an inverse agonist 
might be a better strategy in asthma management 
than use of a β2ADR agonist. An inverse agonist is one 
which stabilises the inactive receptor conformation 
and blocks its constitutive activity by switching oﬀ 
β2ADR signalling.
β antagonists are contra-indicated in patients 
with asthma, even patients using β1 selective 
drugs, because of the eﬀ ects of dose related β2ADR 
blockade, which promotes cholinergic transmission 
and bronchoconstriction, especially upon ﬁ rst dose 
exposure. Therefore to ever consider use of a non-
selective β blocker such as nadolol as anti-asthma 
treatment would seem counterintuitive. 
Some researchers have proposed that switching 
off β2ADR (thereby lowering cAMP) with an inverse 
β2 agonist such as nadolol might paradoxically result 
in an improvement in airway hyper-responsiveness 
and associated control.5 This idea was supported 
by data from knockout mice devoid of β2ADR who, 
when exposed to antigen, did not develop airway 
hyper-responsiveness or other cardinal inflammatory 
features of the asthma phenotype, while the same 
effect also occurred with nadolol treatment in wild 
type mice expressing β2ADR.6 Moreover, nadolol 
confers complimentary corticosteroid sparing anti-
inflammatory activity in the mouse model.7
The beneﬁ cial eﬀ ect of β blockers in adrenaline 
depleted mice was subsequently suggested to be 
ligand speciﬁ c, since exposure to propranolol but not 
nadolol resulted in the development of the asthma 
phenotype, whereas in wild type mice, nadolol but 
not propranolol prevented the occurrence of asthma.8 
Thus nadolol reduces cAMP as a canonical inverse 
agonist and is a non-canonical neutral antagonist 
on ERK1/2,1 resulting in an overall anti-asthmatic 
proﬁ le. Propranolol acts as a so-called biased ligand, 
stimulating ERK1/2 as a non-canonical partial agonist 
while reducing cAMP as a canonical inverse agonist, 
resulting in a net null or pro-asthmatic proﬁ le 
(ﬁ gure).1,8
Studies in people with asthma have revealed 
conflicting results with oral non-selective β blockers. 
Two open-label studies with nadolol (10–40 mg/day) 
in inhaled corticosteroid naive intermittent asthma 
reported improvements in methacholine airway 
hyper-responsiveness.9,10 Under the same reasoning 
that a LABA would never be given without an 
inhaled corticosteroid, nadolol should not be 
given as a monotherapy (ie, without an inhaled 
corticosteroid) either. By contrast, two placebo 
controlled trials of propranolol (20–80 mg/day) in 
